leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 07:35:14 - browse：7172

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Medicare Advantage insurers pressure Biden for bigger payments

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Peter Marks talks Operation Warp Speed for Rare Diseases

What the Wegovy shortage looks like for doctors — and for patients

Mirador, a new biotech startup, launches with $400 million

There’s no way to know how good AI health technologies are

Surgeons perform first xenotransplant using CRISPR'd pig kidney

focus

leisure time

knowledge

Jerome Adams on the need for new antivirals for Covid

Medicare to cover more brain scans related to Alzheimer’s drugs

Cancer drug shortages should be causing more outrage

Testing GLP

What does generative AI mean for health care? We asked experts

What the Wegovy shortage looks like for doctors — and for patients

Novavax promises a turnaround & Lilly roils the obesity market

STAT Readout Newsletter: Today in biotech, life science news

Bright Health sells Medicare Advantage business to Molina

What the Wegovy shortage looks like for doctors — and for patients

explore

Asbestos ban is immediate, but health effects will linger for decades

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Mirador, a new biotech startup, launches with $400 million

Better Therapeutics data on benefit with GLP

Diabetes management: Digital health tools fall short, study says

entertainment

hotspot

focus

focus